Abstract: A native NMOS device includes: a P-type epitaxial layer, a first and a second insulation region, a first P-type well, a second P-type well, a gate, an N-type source, and an N-type drain. The P-type epitaxial layer has a first concentration of P-type doped impurities. The first P-type well completely encompasses and is in contact with a lower surface of the N-type source. The second P-type well completely encompasses and is in contact with a lower surface of the N-type drain. Each of the first P-type well and the second P-type well has a second concentration of P-type doped impurities, and the second concentration of P-type doped impurities is higher than the first concentration of P-type doped impurities. The second concentration of P-type doped impurities is sufficient for preventing a leakage current from flowing between the N-type drain and the P-type substrate while the native NMOS device is in operation.

Abstract: The present invention relates to a benzylamine derivative, a preparation method therefor and use thereof, and in particular, to a benzylamine derivative as represented by general formula (I), or a pharmaceutically acceptable stereoisomer, salt, solvate or prodrug thereof, which has a strong binding capability with human PD-L1, can obviously inhibit the interaction of PD-1/PD-L1, and has significant anti-tumor efficacy in vivo. Therefore, the present invention also relates to a preparation method for the benzylamine derivative and use thereof in preparing a drug for treating PD-1/PD-L1-related diseases.

Abstract: The present invention relates to an application of an artemisinin compound in treatment of coronavirus infection. Specifically, the present invention provides an application of the compound, and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a hydrate thereof in preparation of medicines. The medicines are used for treating diseases or infection caused by coronavirus (preferably SARS-CoV-2), and the compound is selected from one or more of artemisinin, arteether, artemether, artemisia ketone, dihydroartemisinin, artesunate, arteannuin B, and artemisinic acid.

Abstract: The invention relates to a compound represented by general Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable hydrate thereof or pharmaceutically acceptable solvate thereof and the invention also relates to a pharmaceutical composition comprising the compound, and a preparation method for the compound and a use of the compound.

Abstract: The present invention relates to the technical field of chemical drug synthesis, and specifically relates to a method for preparing a compound as shown in formula I, comprising: treating the compound as shown in formula VII with an acid to generate the compound as shown in formula I. The method has few synthetic process steps, raw materials which is stable and is easy to prepare, a reaction process which is easy to control, and a high overall yield and purity, and is suitable for industrial preparation.

Abstract: The present application relates to use of cannabidiol in the preparation of a drug for treating coronavirus infections. The present invention specifically relates to cannabidiol, or a geometric isomer, pharmaceutically acceptable salt, solvate or hydrate thereof, or use of a pharmaceutical composition comprising any one or more of the above components in the preparation of a drug for preventing and/or treating diseases or infections caused by a coronavirus.

Abstract: The present invention relates to an application of benflumetol and derivatives thereof in treatment of coronavirus infection, and specifically provides uses of a compound represented by formula A, and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a hydrate thereof in preparation of drugs. The drugs are used for treating diseases or infection caused by coronavirus (preferably SARS-CoV-2).

Abstract: Disclosed are hydroxychloroquine or chloroquine, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and/or a solvate thereof, and/or a hydrate thereof, and a pharmaceutical composition containing the above-mentioned compound, and the use thereof in the treatment of diseases or infections caused by SARS-CoV-2.

Abstract: Disclosed is a method for preparing a C-nucleoside compound represented by Formula (III) or salt thereof. The present method has a high reaction yield, is simple to operate, uses a single metal reagent, has stable reaction temperature conditions, does not require frequent changes to the reaction system during the operation process, is suitable for scale-up synthesis, is suitable for large-scale production of Remdesivir, and has low costs.

Abstract: Disclosed are the use of a benzoate compound as shown in formula I, a geometric isomer thereof, a pharmaceutically acceptable salt thereof and/or a solvate thereof or a hydrate thereof, and a pharmaceutical composition containing the above-mentioned compound in the prevention and treatment of SARS-CoV-2 infections.

Abstract: A compound represented by the general Formula I, a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and/or a solvate thereof, and/or a hydrate thereof for preventing and/or treating a pulmonary disease or symptom associated with SARS-CoV-2 or an asymptomatic or symptomatic SARS-CoV-2 infection, and an application of the compound represented by the general Formula I, the geometric isomer thereof, or the pharmaceutically acceptable salt thereof, and/or the solvate thereof, and/or the hydrate thereof in preparation of a product for preventing and/or treating a pulmonary disease or symptom associated with SARS-CoV-2 or asymptomatic or symptomatic SARS-CoV-2 infection,

Abstract: Nitazoxanide represented by formula I and an active form thereof, tizoxanide compound, represented by formula II, a geometric isomer thereof and pharmaceutically acceptable salt thereof and/or solvate thereof and/or hydrate thereof, and a pharmaceutical composition containing this compound, used for preventing and/or treating coronavirus (such as SARS-CoV-2) infection.

Abstract: A use of ritonavir, or a geometric isomer, pharmaceutically acceptable salt, solvate, and/or hydrate thereof, and a pharmaceutical composition containing the above compound in treating a SARS-CoV-2 infections.

Abstract: 2-Benzylidene hydrazinoadenosine compounds having A2A adenosine receptor agonistic activity, represented by a general Formula (I) and pharmaceutical compositions containing the same. The compounds and compositions can act as A2A adenosine receptor agonist to serve as medicaments.

Abstract: The present disclosure provides 6-hydrazinoadenosine represented by the general Formula (I) and its derivatives with A2A adenosine receptor agonist activity, and pharmaceutical compositions containing them. The compound and composition can be used as A2A adenosine receptor agonists and used as medicament.

Abstract: The present application provides a small-molecule compound, represented by general Formula (I), having A2A adenosine receptor antagonistic activity and a pharmaceutical composition containing same. The compound and composition can be used as A2A adenosine receptor antagonistic agents.

Abstract: The present invention relates to a compound represented by Formula I, its pharmaceutically acceptable salt, its stereoisomer, its pharmaceutically acceptable hydrate or solvate, or its pharmaceutically acceptable ester, wherein R is selected from heteroaryl, substituted heteroaryl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, alkyl, and substituted alkyl, wherein the substituted heteroaryl, the substituted aryl, the substituted cycloalkyl and the substituted alkyl are each independently substituted with one or more hydroxyalkylene groups. The compound or its pharmaceutically acceptable salt, its stereoisomer, its pharmaceutically acceptable hydrate or solvate, its pharmaceutically acceptable ester of the present invention has agonistic activity on A2A adenosine receptor and can improve the permeability of blood-brain barrier to promote the delivery of drug across blood-brain barrier, and can also prevent or treat a disease associated with A2A adenosine receptor agonistic activity.